Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

Source :: Legal Monitor Worldwide. December 23, 2020
Publication Year :: 2020
Abstract: (GlobeNewswire) - Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences (Nasdaq: NBIX) that it has placed a clinical hold [...]

Subjects :: United States. Food and Drug Administration -- Planning
Neurocrine Biosciences Inc. -- Planning
Biotechnology industry -- Planning
Gene therapy
Company business planning
Business, international
Law

Tools